Literature DB >> 18074401

Newly-developed Sendai virus vector for retinal gene transfer: reduction of innate immune response via deletion of all envelope-related genes.

Yusuke Murakami1, Yasuhiro Ikeda, Yoshikazu Yonemitsu, Sakura Tanaka, Haruhiko Kondo, Shinji Okano, Ri-Ichiro Kohno, Masanori Miyazaki, Makoto Inoue, Mamoru Hasegawa, Tatsuro Ishibashi, Katsuo Sueishi.   

Abstract

BACKGROUND: Recombinant Sendai virus vectors (rSeV) constitute a new class of cytoplasmic RNA vectors that have shown efficient gene transfer in various organs, including retinal tissue; however, the related immune responses remain to be overcome in view of clinical applications. We recently developed a novel rSeV from which all envelope-related genes were deleted (rSeV/dFdMdHN) and, in the present study, assess host immune responses following retinal gene transfer.
METHODS: rSeV/dFdMdHN or conventional F-gene deleted rSeV (rSeV/dF) was injected into subretinal space of adult Wistar rats or C57BL/6 mice. The transgene expression and histopathological findings were assessed at various time points. Immunological assessments, including the expression of proinflammatory cytokines, natural killer (NK)-cell activity, as well as SeV-specific cytotoxic T lymphocytes (CTLs) and antibodies, were performed following vector injection.
RESULTS: rSeV/dFdMdHN showed high gene transfer efficiency into the retinal pigment epithelium at an equivalent level to that seen with rSeV/dF. In the early phase, the upregulation of proinflammatory cytokines, local inflammatory cell infiltration and tissue damage that were all prominently seen in rSeV/dF injection were dramatically diminished using rSeV/dFdMdHN. NK cell activity was also decreased, indicating a reduction of the innate immune response. In the later phase, on the other hand, CTL activity and anti-SeV antibodies were similarly induced, even using rSeV/dFdMdHN, and resulted in transient transgene expression in both vector types.
CONCLUSIONS: Deletion of envelope-related genes of rSeV dramatically reduces the vector-induced retinal damage and may extend the utility for ocular gene transfer; however, further studies regulating the acquired immune response are required to achieve long-term transgene expression of rSeV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18074401     DOI: 10.1002/jgm.1142

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  8 in total

1.  Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming.

Authors:  Ken Nishimura; Masayuki Sano; Manami Ohtaka; Birei Furuta; Yoko Umemura; Yoshiro Nakajima; Yuzuru Ikehara; Toshihiro Kobayashi; Hiroaki Segawa; Satoko Takayasu; Hideyuki Sato; Kaori Motomura; Eriko Uchida; Toshie Kanayasu-Toyoda; Makoto Asashima; Hiromitsu Nakauchi; Teruhide Yamaguchi; Mahito Nakanishi
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

Review 2.  Advances in RNA Viral Vector Technology to Reprogram Somatic Cells: The Paramyxovirus Wave.

Authors:  Brenna Sharp; Ramya Rallabandi; Patricia Devaux
Journal:  Mol Diagn Ther       Date:  2022-06-28       Impact factor: 4.476

3.  Inhibition of nuclear translocation of apoptosis-inducing factor is an essential mechanism of the neuroprotective activity of pigment epithelium-derived factor in a rat model of retinal degeneration.

Authors:  Yusuke Murakami; Yasuhiro Ikeda; Yoshikazu Yonemitsu; Mitsuho Onimaru; Kazunori Nakagawa; Ri-ichiro Kohno; Masanori Miyazaki; Toshio Hisatomi; Makoto Nakamura; Takeshi Yabe; Mamoru Hasegawa; Tatsuro Ishibashi; Katsuo Sueishi
Journal:  Am J Pathol       Date:  2008-10-09       Impact factor: 4.307

Review 4.  Viral and Synthetic RNA Vector Technologies and Applications.

Authors:  Juliane W Schott; Michael Morgan; Melanie Galla; Axel Schambach
Journal:  Mol Ther       Date:  2016-07-05       Impact factor: 11.454

Review 5.  RNA-based tools for nuclear reprogramming and lineage-conversion: towards clinical applications.

Authors:  Juan A Bernal
Journal:  J Cardiovasc Transl Res       Date:  2013-07-13       Impact factor: 4.132

Review 6.  Gene therapy in animal models of autosomal dominant retinitis pigmentosa.

Authors:  Brian Rossmiller; Haoyu Mao; Alfred S Lewin
Journal:  Mol Vis       Date:  2012-10-06       Impact factor: 2.367

Review 7.  Development of Sendai virus vectors and their potential applications in gene therapy and regenerative medicine.

Authors:  Mahito Nakanishi; Makoto Otsu
Journal:  Curr Gene Ther       Date:  2012-10       Impact factor: 4.391

8.  Development of a Safeguard System Using an Episomal Mammalian Artificial Chromosome for Gene and Cell Therapy.

Authors:  Narumi Uno; Katsuhiro Uno; Shinya Komoto; Teruhiko Suzuki; Masaharu Hiratsuka; Mitsuhiko Osaki; Yasuhiro Kazuki; Mitsuo Oshimura
Journal:  Mol Ther Nucleic Acids       Date:  2015-12-15       Impact factor: 10.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.